About this trial
Debate continues on whether or not male homosexuality (MH) is a result of biological or cultural factors. The debate persists despite the fact that these two sides have different abilities to create a scientific environment to support their cause. Biological theorists produced evidence, however, that these are not always robust. On the other hand, social theorists, without direct evidence confirming their positions, criticize, with good argument, methods and results of the other side.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18 years
Male will be included
Disqualifiers
Patients taking testosterone or its derivative.
Patients taking anabolic steroids.
Multi-sexual behaviours.
HIV patients.
Trial population
All individuals with homosexuality from these different locations, Egypt, England, China, and Mexico.
Trial design
Ecologic or community
Prospective
Treatments tested in this trial
Subjective Scale of Stigma and Discrimination (SISD).
BehavioralSubjective Scale of Stigma and Discrimination (SISD) A sixdimension self-administered scale will be used that included statements with which the participants agreed or disagreed. The scale consists of 23 Likert-type items and responses range from 1 ("completely in disagreement") to 5 ("completely in agreement"), grouped together to represent the six indicators making up this part of the scale
Treatment groups
Trial outcomes
Primary outcomes
Change of Symptom Checklist-90-Revised (SCL-90-R) from baseline to 34 weeks
The SCL-90-R Is an inventory developed to assess the intensity of symptoms inventoried during the last weeks. Each of the 90 items that is integrated in the self-report questionnaire is answered in a likert scale from 0 (nothing) to 4 (a lot), depending on the intensity with which the subject has lived in the last weeks the discomfort that each one explores. It is evaluated and interpreted in function of 10 primary dimensions (somatization, obsession-compulsion, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, psychotic and diverse symptoms and three global indexes of psychological disorders.
Change of Sexual Compulsivity Scale (SCS) from baseline to 34 weeks
The SCS contains 10 items (e.g., "my desires to have sex have disrupted my daily life"), rated from 1 (not at all like me) to 4 (very much like me). Item responses are summed to derive an overall score (range 10-40). A score of 24 or higher is frequently used to distinguish problematic sexual compulsivity
Change of Safer Sex Self-Efficacy Questionnaire (SSSE) from baseline to 34 weeks
The 13-item SSSE assesses self-efficacy for condom use in various situations (e.g., "When you really need affection," "When your partner says he/she does not want to use a condom") in response to the prompt, "How confident are you that you could avoid having anal sex without a condom?" using a scale ranging from 1 (not at all tempted) to 5 (extremely tempted). The SSSE predicts condomless anal intercourse among men who have sex with men (MSM; Rendina, 2014).
Secondary outcomes
Change of Measure of Gay-Related Stress (MOGS) from baseline to 34 weeks
The MOGS contains 56 stressors related to being gay, which participants rated in terms of the negative and positive impact each stressor had if it occurred in the past 12 months along a scale ranging from -3 (extremely negative) to 3 (extremely positive).
Change of Internalized Homophobia Scale (IHP) from baseline to 34 weeks
The IHP assesses how troubled gay and bisexual men are about their sexual identities over the past year. Participants rate nine items using a scale from 1 (never) to 4 (often). The IHP is associated with general mental and sexual health problems in a sample of adult gay men (Meyer, 1995).
Change of Sexual Orientation Concealment Scale (SOCS) from baseline to 34 weeks
In the SOCS, participants indicate the degree to which they are "out of the closet" to five domains of people: family; gay, lesbian, and bisexual friends; straight friends; co-workers; and health care providers, using a scale from 1 (out to all) to 4 (out to none).
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Mostafa Bahaa
Lead sponsor
Tanta University
Sponsor institution
Mostafa Mahmoud Bahaa Clinical Pharmacy Department, Horus University, New Damietta, Egypt
Collaborator